Abstract
The efficacy and tolerability of donepezil (Alzepil) in the treatment of undifferentiated dementia in 52 patients (mean age 77 ± 8,2 years at the time of inclusion) with cerebrovascular disease (CVD) were investigated. Patients were divided into groups based on the genetically determined factor - the rate of passive transmembrane ion transport (PTIT) which determines both the severity of the disease and its response to therapy. PTIT rate was determined by the rate of Na-Li countertransport (NLC) in the erythrocyte membrane. Patients with high NLC rates had more severe dementia and better responded to treatment. Therefore, evaluation of NLC rate is a promising research method in terms of predicting the disease severity and response to treatment. In general, donepezil (Alzepil) demonstrated good efficacy and tolerability in patients with dementia and CVD regardless of the neuropsychological profile, justifying its use in any type of dementia.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
